The most useful questions to ask before GHK-Cu cover the goal, what the studies actually tested, copper exposure and medical history. Cancer history, pregnancy, skin reactions, other products and tested sport all belong in the conversation. So does a plan for deciding whether to continue.

GHK-Cu is a peptide, a short chain of protein building blocks, bound to copper. The broader guide to what GHK-Cu does explains its biology. These ten questions explain what a provider needs to review, and why.

Questions to ask before GHK-Cu: evidence and copper

1. Which human studies match my goal and the proposed route?

The provider needs a specific concern, previous treatments and the preparation being considered. Topical means applied to the skin. Human findings from topical products cannot establish what an injection does.

In Miller and colleagues' 2006 trial in Archives of Facial Plastic Surgery, patients used skin-care regimens after laser treatment. Satisfaction favored GHK-Cu, but measured redness, wrinkles and overall skin quality did not differ between groups. The clinical-evidence guide examines those findings; the hair evidence answers a separate question.

GHK-Cu has no FDA-approved drug label. Through Promise, it is dispensed as a compounded medication, meaning a pharmacy prepares it for a prescription. That is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor.

As of October 1, 2026, the day this article was written, FDA's document marked “Updated May 14, 2026” still separates non-injectable use from the withdrawn injectable nomination. The GHK-Cu FDA review explains the record. It doesn't supply a treatment protocol.

2. How will my medicines, supplements and other copper sources be assessed?

The review includes prescription medicines, supplements and copper-containing products. NIH's copper fact sheet lists the upper intake limit for adults aged 19 and older as “10,000 mcg” daily, or 10 mg. That limit concerns copper from food and supplements in healthy people. It isn't an injection safety limit.

As of October 1, 2026, the day this article was written, an August 27 Pharmaceutics review highlights a further gap. Studies often don't establish how much copper remains attached to GHK or how much reaches tissues. Long-term copper exposure from injected GHK-Cu hasn't been established. The dosage discussion explains why the prescriber sets the amount.

3. What do Wilson disease, liver problems or kidney problems change?

Wilson disease is an inherited condition that prevents normal removal of excess copper. NIDDK explains that copper can build up in the liver, brain and other organs. Other diagnosed copper-handling disorders and unexplained copper-test results also belong in the history.

Most copper leaves through bile, the digestive fluid made by the liver; only a small amount leaves in urine, according to NIH. That makes liver and bile-duct history especially relevant. Kidney disease belongs in the wider health review, but kidneys aren't the main copper exit. The provider considers existing diagnoses, treatment and laboratory results together.

4. How does current or past cancer affect the discussion?

The provider needs the diagnosis, treatment history and ongoing cancer care. The question comes from tissue-repair biology, rather than a demonstrated cancer risk in people taking GHK-Cu.

Sen and colleagues' 2002 study examined copper's effects on blood-vessel growth signals in cells and mouse wounds. It tested copper sulfate, not GHK-Cu. Pickart and Margolina's 2018 review discusses angiogenesis, meaning new blood-vessel growth, and raises the cancer question around tissue remodeling. Laboratory gene findings don't settle safety during cancer care. The broader peptides and cancer discussion separates these mechanisms.

5. What does pregnancy, trying to conceive or breastfeeding change?

Human GHK-Cu safety data for pregnancy and breastfeeding are missing. Finding copper in ordinary nutrition or GHK in the body doesn't answer what an added preparation does during pregnancy.

The provider needs pregnancy status, plans and breastfeeding details. As of October 1, 2026, the day this article was written, the CuHeal wound-study record, last updated February 27, 2026, excludes pregnant and breastfeeding participants. That study cannot answer these safety questions.

Skin products and earlier reactions

6. How do metal allergies, sensitive skin and retinoids affect the review?

The provider wants the actual reaction: the product or metal involved, symptoms and timing. A metal allergy doesn't automatically establish a copper allergy, and irritation isn't always an allergy.

Retinoids are vitamin A-based skin treatments, including retinol and prescription products. The American Academy of Dermatology explains that they can irritate skin. Current retinoids, acids, fragrances and recent procedures help explain existing redness or dryness. The GHK-Cu versus retinol comparison covers the treatment evidence.

7. What do previous injection-site reactions tell us?

Earlier redness, swelling, hives or dizziness matter even when the cause wasn't identified. Product names and the timing of symptoms help the provider assess the pattern.

As of October 1, 2026, the day this article was written, FDA's safety page, marked current as of April 22, 2026, identifies limited human safety data for injectable GHK-Cu. It describes possible unwanted immune responses, reactions from the body's defenses, related to peptide clumping or impurities. These are concerns, not measured reaction rates. The side-effects guide covers symptoms by route.

Sport testing belongs in the visit

8. Could my competition rules prohibit the proposed preparation?

The provider needs to know about tested sport and future competition. A prescription alone doesn't establish permission under sport rules.

As of October 1, 2026, the day this article was written, the World Anti-Doping Agency, or WADA, has published its 2027 list on September 21. It starts January 1, 2027; the 2026 list applies until then. The new list doesn't name GHK-Cu. Its explanatory note says unnamed peptides may still be prohibited under S0, the class for non-approved substances, or other classes. The sport-rules guide explains why a missing name isn't clearance.

The same ingredient can appear twice

9. Does anything I already use contain GHK-Cu?

The review includes skin-care labels and other peptide products. KLOW and Glow both contain GHK-Cu alongside other peptides. Adding GHK-Cu separately creates overlapping exposure; the different product names don't make the ingredient different.

The provider considers the complete preparations and the reason for combining them. Separate ingredient studies cannot establish a blend's effects. Several products changed together also make a new reaction harder to attribute.

Follow-up needs a starting point

10. What would count as progress, and what would lead to stopping?

The discussion needs a starting measure, a follow-up date and a named contact for concerns. Depending on the goal, progress might involve a clinician's skin assessment or a consistent symptom measure. Satisfaction alone cannot show that GHK-Cu caused a change.

New symptoms, no meaningful progress or a changed diagnosis can lead the provider to reassess or stop treatment. The plan also identifies which symptoms need prompt contact and how a suspected reaction will be evaluated.

At Promise, a licensed provider reviews every request, and not everyone qualifies.